

BIOGRAPHICAL SKETCH

Name: [Last, First, Middle Initial(s), Degree(s)] Laroni, Alice, M.D. Ph.D.	Position/Title: Assistant Professor of Neurology
--	---

Education

Institution and Location	Degree	Year Conferred	Field of Study
Liceo Ginnasio Statale Raimondo Franchetti, Venezia	Maturità Classica, 60/60	1997	Liceo Classico
University of Padova, Padova, Italy	M.D. Summa cum laude	2003	Medicine and Surgery
University of Padova, Padova, Italy	Neurologist, Summa cum laude	2009	Neurology
University of Genova, Genova, Italy	PhD	2015	Neuroscience

Research and Professional Experience

May 2004-January 2009: Neurology Resident, University of Padova, Padova, Italy

March 31, 2008 – July 9, 2009 Research Fellow
Laboratory of Howard L. Weiner, Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard University, Boston, MA, USA.

January 1, 2010 – December 31, 2011: Research fellow, Fondazione Italiana Sclerosi Multipla, at University of Genova, Genova, Italy

September 1, 2009 – December 31st, 2011 Research Fellow, University of Genova, Genova, Italy

March 16, 2011, to date. Member of the Scientific Committee of the Italian branch of the Mesenchymal Stem Cells for Multiple Sclerosis trial and of the Trial Management group of its International consortium

January 1, 2012- April 29, 2015: PhD Student, University of Genova, Genova, Italy

October 9, 2012- to date. Member of the Bio-MS Eu- Consortium for CSF Biomarker research

October 1, 2014, to date. Assistant Professor of Neurology University of Genova, Genova, Italy.

February 1, 2016, to date. Co-affiliation to IRCCS Azienda Ospedaliera San Martino-IST, Genova, Ita

Grants and Awards

2009 Research Fellowship from Fondazione Italiana Sclerosi Multipla (FISM) (Prot. N. 297/09/F14) with the title “Dissection of the role of CD56^{bright} NK cells in multiple sclerosis”.

Rita Levi Montalcini research prize, Italian Multiple Sclerosis Society (Fondazione Italiana Sclerosi Multipla). May 25, 2016.

Best Poster Award, Annual Conference of the Italian Neurology Society, October 11, 2015.

Special Award of the Jury-Premio Aldo Fasolo 2016 (science dissemination)

“Prag-MS”, 4-year project funded by PCORI (“Patient-Centered Outcomes Research Institute”). Role in project: Partner.

Memberships: International Society for Neuroimmunology, Italian Society for Neuroimmunology, Italian Neurological Society.

Author of 29 publications in peer-reviewed international journals.

H Index: 18

Number of citations in last 10 years: 1976

Selected Publications

1. Sormani MP, Laroni A. Approved drugs for MS: the challenge of choice. Editorial. The Lancet Neurology, Published Online February 10, 2017 [http://dx.doi.org/10.1016/S1474-4422\(17\)30021-2](http://dx.doi.org/10.1016/S1474-4422(17)30021-2)
2. Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A. Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. *Front Immunol.* 2016 Dec 19;7:606. doi: 10.3389/fimmu.2016.00606
3. Gandoglia I, Ivaldi F, Carrega P, Armentani E, Ferlazzo G, Mancardi G, Kerlero de Rosbo N, Uccelli A, Laroni A. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. *Immunol Lett.* 2017 Jan;181:109-115. doi: 10.1016/j.imlet.2016.11.015.
4. Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. *Neurol Sci.* 2016 Oct 18. [Epub ahead of print]
5. Laroni A., Armentani E., Kerlero de Rosbo N., Ivaldi F., Marcenaro E., Sivori S., Gandhi R., Weiner HL, Moretta A., Mancardi GL, Uccelli A. Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. *J. Autoimmunity, Journal of Autoimmunity* (2016), <http://dx.doi.org/10.1016/j.jaut.2016.04.003>
6. Laroni A, Rosbo NK, Uccelli A. Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. *Immunol Lett.* 2015 Aug 18. pii: S0165-2478(15)30021-3. doi: 10.1016/j.imlet.2015.08.007.
7. Kuhle J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. *Mult Scler.* 2015 Feb 13. pii: 1352458514568827.
8. Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. *BMC Neurol.* 2014 May 12;14:103
9. Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL; EAP Investigators. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. *BMC Neurol.* 2014 Apr 1;14:65. doi: 10.1186/1471-2377-14-65
10. Laroni A, Novi G, Kerlero de Rosbo N, Uccelli A. Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. *J Neuroimmune Pharmacol.* 2013 Dec;8(5):1062-76. doi: 10.1007/s11481-013-9456-6. Epub 2013 Apr 12.
11. Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. *Mult Scler.* 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26
12. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS - progress to date. *Mult Scler.* 2013 Apr;19(5):515-9. doi: 10.1177/1352458512464686. Epub 2012
13. Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. *J Neuroimmune Pharmacol.* 2012 Sep;7(3):665-72.
14. Sallusto F, Impellizzeri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B. T-cell trafficking in the central nervous system. *Immunol Rev.* 2012 Jul;248(1):216-27
15. Laroni A, Gandhi R, Beynon V., Weiner HL. IL-27 imparts immunoregulatory function to human NK cell subsets *PLoS One.* 2011;6(10):e26173
16. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. *Lancet Neurol.* 2011 Jul;10(7):649-56.
17. Uccelli A, Benvenuto F, Laroni A, Giunti D. Neuroprotective features of mesenchymal stem cells. *Best Pract Res Clin Haematol.* 2011 Mar;24(1):59-64. Epub 2011 Feb 25.
18. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. *Nat Immunol.* 2010 Sep;11(9):846-53.
19. Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L. Three years of experience: the Italian registry and safety data update. *Neurol Sci.* 2011 Jan;31 Suppl 3:295-7.
20. Gandhi R and Laroni A*, Weiner H.L. The role of the Innate Immune System in the pathogenesis of Multiple Sclerosis, *J Neuroimmunol.* 2010 Apr 15;221(1-2):7-14. Laroni and R. Gandhi contributed equally to this work
21. Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, Tiberio M, Battistin L, Gallo P., Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy, *J Neurol.* 2006; 253(5): 636-9

Shulaver